Ignite Creation Date:
2024-05-06 @ 2:45 AM
Last Modification Date:
2024-10-26 @ 11:22 AM
Study NCT ID:
NCT02115295
Status:
RECRUITING
Last Update Posted:
2024-04-25
First Post:
2014-04-14
Brief Title:
Cladribine Idarubicin Cytarabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia High-Risk Myelodysplastic Syndrome or Blastic Phase Chronic Myeloid Leukemia
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Untreated Adult Acute Myeloid Leukemia |
| Acute Biphenotypic Leukemia |
| Acute Myeloid Leukemia |
| Blast Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive |
| Blasts 10 Percent or More of Bone Marrow Nucleated Cells |
| Blasts 10 Percent or More of Peripheral Blood White Cells |
| de Novo Myelodysplastic Syndrome |
| Myelodysplastic Syndrome |
| Previously Treated Myelodysplastic Syndrome |
| Recurrent Acute Myeloid Leukemia |
| Recurrent Chronic Myelogenous Leukemia BCR-ABL1 Positive |
| Refractory Acute Myeloid Leukemia |
| Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive |
| Secondary Acute Myeloid Leukemia |
Keywords: